{"id":91238,"date":"2026-07-27T12:25:17","date_gmt":"2026-07-27T12:25:17","guid":{"rendered":"https:\/\/www.europesays.com\/britain\/91238\/"},"modified":"2026-07-27T12:25:17","modified_gmt":"2026-07-27T12:25:17","slug":"astrazeneca-profit-rises-on-strong-cancer-drug-sales-2","status":"publish","type":"post","link":"https:\/\/www.europesays.com\/britain\/91238\/","title":{"rendered":"AstraZeneca profit rises on strong cancer drug sales"},"content":{"rendered":"

<\/a> AstraZeneca reconfirmed its outlook for the full year (Hector RETAMAL) <\/p>\n

British pharmaceutical giant AstraZeneca on Monday said net profit rose in the second quarter, driven once again by strong growth in sales of its cancer drugs. <\/p>\n

Profit after tax climbed more than two percent to $2.5 billion in the three months to the end of June, compared with the same period last year, AstraZeneca said in a results statement. <\/p>\n

Group revenue increased six percent to $15.4 billion in the quarter, thanks to sustained strong demand for its cancer and rare disease medicines.\u00a0 <\/p>\n

AstraZeneca reconfirmed its outlook for the full year after its latest profit beat analyst expectations.\u00a0 <\/p>\n

Chief executive Pascal Soriot said the company was “on track” to deliver its ambition of $80 billion in total revenue by 2030, despite an unexpected late-stage trial failure earlier this month.\u00a0 <\/p>\n

Shares in the company had slumped in early July after its new heart disease drug Wainua failed to meet targets, in a rare setback for the drugmaker.\u00a0 <\/p>\n

“People have got used to us delivering with a high success rate but we have to accept we will fail from time to time,” Soriot said on a media call Monday.\u00a0 <\/p>\n

“Overall, we are making good progress with a very high success rate across our portfolio,” he added. <\/p>\n

AstraZeneca shares rose almost two percent in midday trading on London’s FTSE 100 index, which was trading higher overall.\u00a0 <\/p>\n

“Soriot stuck to full-year sales and profits guidance and reassuring updates on the drug development pipeline also helped to boost the shares,” said AJ Bell investment director Russ\u00a0Mould. <\/p>\n

Alongside its blockbuster cancer drugs, the company has been investing in developing a weight-loss treatment.\u00a0 <\/p>\n

Last month’s trial results showed that its new pill appears to help people lose a similar amount of weight to other GLP-1 oral drugs. <\/p>\n

If confirmed by further research, the pill could mark AstraZeneca’s entrance into the massively lucrative weight-loss drug market currently dominated by Denmark’s Novo Nordisk and American giant Eli Lilly. <\/p>\n

ajb\/bcp\/rl <\/p>\n","protected":false},"excerpt":{"rendered":"AstraZeneca reconfirmed its outlook for the full year (Hector RETAMAL) British pharmaceutical giant AstraZeneca on Monday said net…\n","protected":false},"author":2,"featured_media":91239,"comment_status":"","ping_status":"","sticky":false,"template":"","format":"standard","meta":{"footnotes":"","_share_on_mastodon":"0"},"categories":[20662],"tags":[11153,1852,37146,11314,36788,9661,11316,29077],"class_list":["post-91238","post","type-post","status-publish","format-standard","has-post-thumbnail","category-astrazeneca","tag-astrazeneca","tag-cancer","tag-cancer-drugs","tag-drug-development","tag-net-profit","tag-outlook","tag-pascal-soriot","tag-pharmaceutical-giant"],"share_on_mastodon":{"url":"https:\/\/pubeurope.com\/@UnitedKingdom\/116991932684407624","error":""},"_links":{"self":[{"href":"https:\/\/www.europesays.com\/britain\/wp-json\/wp\/v2\/posts\/91238","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/www.europesays.com\/britain\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/www.europesays.com\/britain\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/www.europesays.com\/britain\/wp-json\/wp\/v2\/users\/2"}],"replies":[{"embeddable":true,"href":"https:\/\/www.europesays.com\/britain\/wp-json\/wp\/v2\/comments?post=91238"}],"version-history":[{"count":0,"href":"https:\/\/www.europesays.com\/britain\/wp-json\/wp\/v2\/posts\/91238\/revisions"}],"wp:featuredmedia":[{"embeddable":true,"href":"https:\/\/www.europesays.com\/britain\/wp-json\/wp\/v2\/media\/91239"}],"wp:attachment":[{"href":"https:\/\/www.europesays.com\/britain\/wp-json\/wp\/v2\/media?parent=91238"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/www.europesays.com\/britain\/wp-json\/wp\/v2\/categories?post=91238"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/www.europesays.com\/britain\/wp-json\/wp\/v2\/tags?post=91238"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}